{"ticker": {"uuid": "7432b539-d224-4ba3-bbfa-91bdc83d9f95", "symbol": "TIL", "name": "Instil Bio Inc.", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNYmZ3aHMyMjBuNmlEUGN6NWZBZV85cEFWNndJaVNoNEVYNk84MlNKRXJ0RXpRQl9wN1RsekhxM3loY1RRNDJhTnVremtReHhLQWVHS053VzRBUTduSkdqRGt1YkxMMThqZHoydElPX1Zfd3hEMi15VlRwRGRvZ2JqRDFneVVxN0JCYzQ4QlV5TTBEOWx3?oc=5", "source_name": "Market source", "published_at": "2026-07-16T18:49:22+00:00", "published_display": "16 Jul 2026 18:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Avoiding Lag: Real-Time Signals in (TIL) Movement", "summary": "This article analyzes Instil Bio Inc. (NYSE: TIL) using AI models to provide real-time trading signals and strategies. It identifies stable neutral readings in shorter horizons potentially easing long-term weak bias and notes compelling upside potential with no resistance levels ", "url": "https://news.stocktradersdaily.com/news_release/132/Avoiding_Lag:_Real-Time_Signals_in_TIL_Movement_071126044402_1783802642.html", "source_name": "Stock Traders Daily", "published_at": "2026-07-11T16:44:00", "published_display": "11 Jul 2026 16:44", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bronstein, Gewirtz & Grossman, LLC Encourages Instil Bio, Inc. (TIL) Investors to Inquire about Securities Investigation", "summary": "Bronstein, Gewirtz & Grossman, LLC is investigating potential securities claims against Instil Bio, Inc. (NASDAQ:TIL) after its subsidiary, Axion Bio, Inc., announced the discontinuation of clinical development for AXN-2510 and termination of a licensing agreement with ImmuneOnco", "url": "https://natlawreview.com/press-releases/bronstein-gewirtz-grossman-llc-encourages-instil-bio-inc-til-investors", "source_name": "The National Law Review", "published_at": "2026-07-03T12:11:39", "published_display": "03 Jul 2026 12:11", "sentiment": "negative", "sentiment_pct": 19, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of Instil Bio, Inc. \u2013 NASDAQ:TIL", "summary": "This article focuses solely on the \"Price to book forward\" metric for Instil Bio, Inc. (NASDAQ: TIL). The content indicates no specific value, change, or percentage change for this financial metric, stating \"No trades\" and \"Market closed\" in the overview section. The page appears", "url": "https://www.tradingview.com/symbols/NASDAQ-TIL/financials-statistics-and-ratios/price-book-fwd/", "source_name": "TradingView", "published_at": "2026-07-03T09:40:36", "published_display": "03 Jul 2026 09:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBIT forward of Instil Bio, Inc. \u2013 NASDAQ:TIL", "summary": "This page provides financial information for Instil Bio, Inc. (NASDAQ: TIL) on TradingView, specifically focusing on its enterprise value to EBIT forward. The content is primarily a data placeholder within the financial section for the company on the platform.", "url": "https://www.tradingview.com/symbols/NASDAQ-TIL/financials-statistics-and-ratios/enterprise-value-ebit-fwd/", "source_name": "TradingView", "published_at": "2026-06-30T04:40:10", "published_display": "30 Jun 2026 04:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Instil Bio, Inc. \u2013 NASDAQ:TIL", "summary": "This article provides the \"Price to sales forward\" value for Instil Bio, Inc. (NASDAQ: TIL) as listed on TradingView. It appears to be a financial data point without further analysis or context within the presented content. The article indicates the market was closed and no trade", "url": "https://www.tradingview.com/symbols/NASDAQ-TIL/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-29T12:11:30", "published_display": "29 Jun 2026 12:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Instil Bio, Inc. Actuals & Estimates (NASDAQ:TIL)", "summary": "This article provides an overview of Instil Bio, Inc. (NASDAQ:TIL) stock, including its current price, historical performance, analyst forecasts, and financial data. It highlights the stock's recent decline, market capitalization, and upcoming earnings report, while reiterating t", "url": "https://www.tradingview.com/symbols/NASDAQ-TIL/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T16:40:37", "published_display": "26 Jun 2026 16:40", "sentiment": "negative", "sentiment_pct": 18, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "5GT0 Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "This article provides a forecast for Instil Bio, Inc. (5GT0) stock, including a 1-year price target of 6.02 EUR based on one analyst's opinion. It also covers financial details such as past earnings, net income, upcoming earnings dates, and historical stock prices. The Q&A sectio", "url": "https://www.tradingview.com/symbols/TRADEGATE-5GT0/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-26T07:11:14", "published_display": "26 Jun 2026 07:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "TIL Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "This article provides a forecast and price target for Instil Bio, Inc. (TIL) stock, noting analysts' opinions for its future price. It also covers the stock's current performance, historical highs and lows, volatility, market capitalization, and upcoming earnings report. The comp", "url": "https://www.tradingview.com/symbols/NASDAQ-TIL/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-25T17:11:14", "published_display": "25 Jun 2026 17:11", "sentiment": "negative", "sentiment_pct": 38, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Instil Bio Inc (TIL) Technical Analysis: Support, Resistance, Indicators & Moving Averages", "summary": "This article provides a technical analysis of Instil Bio Inc (TIL), outlining its current price momentum, support and resistance levels, and indicator and moving average signals. The stock's current price momentum score is 5.85, and it is trading between a resistance of $8.04 and", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-til/technical", "source_name": "TradingKey", "published_at": "2026-06-24T16:11:14", "published_display": "24 Jun 2026 16:11", "sentiment": "negative", "sentiment_pct": 18, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Instil Bio (Nasdaq:TIL) - Stock Analysis", "summary": "This report provides a comprehensive stock analysis of Instil Bio (Nasdaq: TIL), a biopharmaceutical company with a market cap of US$51.3 million. It details the company's valuation, future growth prospects, past performance, financial health, and dividend policy, noting its curr", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-til/instil-bio", "source_name": "Simply Wall Street", "published_at": "2026-06-23T03:40:37", "published_display": "23 Jun 2026 03:40", "sentiment": "negative", "sentiment_pct": 30, "event_type": "capital_return", "event_label": "Capital return", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Behavioral Patterns of TIL and Institutional Flows", "summary": "This article from Stock Traders Daily discusses the behavioral patterns of Instil Bio Inc. (NYSE: TIL) and institutional flows. It highlights weak sentiment across all horizons supporting a short bias, identifies no clear price positioning signal, and notes no resistance levels a", "url": "https://news.stocktradersdaily.com/news_release/141/Behavioral_Patterns_of_TIL_and_Institutional_Flows_061926022402_1781893442.html", "source_name": "Stock Traders Daily", "published_at": "2026-06-19T14:24:00", "published_display": "19 Jun 2026 14:24", "sentiment": "negative", "sentiment_pct": 39, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Instil Bio Inc (TIL) Valuation: PE, PB & Fair Value Analysis", "summary": "Instil Bio Inc (TIL) currently has a valuation score of 8.27, placing it 154th out of 389 companies in the Biotechnology & Medical Research industry. Its P/E ratio is -1.07, significantly below its recent high but above its recent low. The company has not yet disclosed relevant d", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-til/company-valuation", "source_name": "TradingKey", "published_at": "2026-06-18T13:41:14", "published_display": "18 Jun 2026 13:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Instil Bio Inc (TIL) Institutional Confidence", "summary": "Instil Bio Inc (TIL) has an institutional shareholding score of 5.00, ranking 133rd in the Biotechnology & Medical Research industry. The institutional shareholding proportion is 67.86%, showing a quarter-over-quarter decrease of 0.00%. James Simons is the largest institutional s", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-til/sentiment", "source_name": "TradingKey", "published_at": "2026-06-17T21:09:29", "published_display": "17 Jun 2026 21:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Instil Bio Inc (TIL) Financial Health: Profitability & Balance Sheet Analysis", "summary": "Instil Bio Inc (TIL) has a current financial score of 6.26, ranking 269 out of 388 in the Biotechnology & Medical Research industry, indicating stable financial health but low operating efficiency. The analysis highlights that several key financial data points for categories like", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-til/financial-health", "source_name": "TradingKey", "published_at": "2026-06-17T21:09:29", "published_display": "17 Jun 2026 21:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Instil Bio Inc (TIL) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution", "summary": "The article discusses Instil Bio Inc (TIL)'s revenue breakdown, specifically focusing on its business segments, regional revenue, and profit contribution. It states that relevant financial data for these categories has not yet been disclosed by the company. TradingKey provides th", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-til/revenue", "source_name": "TradingKey", "published_at": "2026-06-17T08:40:07", "published_display": "17 Jun 2026 08:40", "sentiment": "positive", "sentiment_pct": 72, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Instil Bio Inc (TIL) Dividends & Stock Splits: Historical Payouts and Event Timeline", "summary": "This article provides an overview of Instil Bio Inc (TIL)'s dividend history and stock split events. It indicates that the company has not distributed any dividends over the past five years. The article also lists several stock split events, all described as \"Merger 20\u21921\" that oc", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-til/dividend-splits", "source_name": "TradingKey", "published_at": "2026-06-17T08:40:07", "published_display": "17 Jun 2026 08:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Instil Bio Inc (TIL) Earnings Forecast: Future EPS & Revenue Growth Estimates", "summary": "Instil Bio Inc (TIL) has an earnings forecast score of 8.00, placing it 163rd in its industry. Analysts have set an average price target of $88.00 for TIL, with a range from $27.00 to $180.00. Based on ratings from 3 analysts, the general consensus for Instil Bio Inc's stock is a", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-til/earnings", "source_name": "TradingKey", "published_at": "2026-06-17T01:10:15", "published_display": "17 Jun 2026 01:10", "sentiment": "positive", "sentiment_pct": 63, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Instil Bio (NASDAQ: TIL) director receives grant of 6,500 stock options", "summary": "Instil Bio director George Matcham has been granted 6,500 stock options with an exercise price of $7.93 per share. These options will vest in 12 equal monthly installments beginning July 11, 2026, contingent on his continuous service. Unvested portions will fully vest at the next", "url": "https://www.stocktitan.net/sec-filings/TIL/form-4-instil-bio-inc-insider-trading-activity-18671281c2d0.html", "source_name": "Stock Titan", "published_at": "2026-06-12T18:39:32", "published_display": "12 Jun 2026 18:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Instil Bio (TIL) director Gwendolyn Binder awarded 6,500 stock options at $7.93", "summary": "Instil Bio, Inc. Director Gwendolyn Binder has been awarded 6,500 stock options with an exercise price of $7.93 per share. These options are compensation, not a direct purchase, and will vest in 12 monthly installments starting July 11, 2026, contingent on her continuous service.", "url": "https://www.stocktitan.net/sec-filings/TIL/form-4-instil-bio-inc-insider-trading-activity-bd725b906e02.html", "source_name": "Stock Titan", "published_at": "2026-06-12T18:39:32", "published_display": "12 Jun 2026 18:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Instil Bio (TIL) director awarded 6,500 stock options at $7.93 strike", "summary": "Instil Bio director Neil W. Gibson has been granted 6,500 stock options with an exercise price of $7.93 per share, expiring on June 10, 2036. The options will vest in 12 monthly installments starting July 11, 2026, subject to Gibson's continuous service. This grant is a compensat", "url": "https://www.stocktitan.net/sec-filings/TIL/form-4-instil-bio-inc-insider-trading-activity-131178f28e56.html", "source_name": "Stock Titan", "published_at": "2026-06-12T18:39:32", "published_display": "12 Jun 2026 18:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Instil Bio (TIL) director awarded stock options for 6,500 shares at $7.93", "summary": "Instil Bio director R. Kent McGaughy Jr. received a stock option grant for 6,500 shares at an exercise price of $7.93 per share. These options will vest in 12 equal monthly installments starting July 11, 2026, contingent on his continuous service, with full vesting upon certain e", "url": "https://www.stocktitan.net/sec-filings/TIL/form-4-instil-bio-inc-insider-trading-activity-037edc7bdbfd.html", "source_name": "Stock Titan", "published_at": "2026-06-12T04:10:16", "published_display": "12 Jun 2026 04:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[8-K] Instil Bio, Inc. Reports Material Event", "summary": "Instil Bio, Inc. announced the results of its 2026 Annual Meeting of Stockholders. Shareholders elected George Matcham and Neil Gibson as Class II directors and ratified RSM US LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026. ", "url": "https://www.stocktitan.net/sec-filings/TIL/8-k-instil-bio-inc-reports-material-event-c84e8705d1bf.html", "source_name": "Stock Titan", "published_at": "2026-06-11T20:10:32", "published_display": "11 Jun 2026 20:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "(TIL) Movement Within Algorithmic Entry Frameworks", "summary": "This article analyzes Instil Bio Inc. (NYSE: TIL) through algorithmic entry frameworks, noting stable neutral readings in shorter horizons and potential easing of a long-term weak bias. No clear price positioning signal is identified, but the absence of resistance levels above th", "url": "https://news.stocktradersdaily.com/news_release/150/TIL_Movement_Within_Algorithmic_Entry_Frameworks_060826011602_1780938962.html", "source_name": "Stock Traders Daily", "published_at": "2026-06-08T13:16:00", "published_display": "08 Jun 2026 13:16", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "TIL - Instil Bio Inc Stock Price and Quote", "summary": "This article provides a detailed overview of Instil Bio Inc (TIL) stock, including its current price, financial metrics, performance indicators, analyst ratings, and recent news. It highlights the company's financial state, insider transactions, and clinical development updates r", "url": "https://finviz.com/stock?t=TIL", "source_name": "Finviz", "published_at": "2026-05-30T18:40:10", "published_display": "30 May 2026 18:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Instil Bio, Inc. Reports First Quarter 2026 Financial Results \u2013 8-K Filing Details and Key Highlights", "summary": "Instil Bio, Inc. (Nasdaq: TIL) released its Q1 2026 financial results, highlighting a strong cash position of $74.7 million expected to fund operations beyond 2027. The company is actively evaluating potential acquisitions and in-licensing opportunities, while significantly reduc", "url": "https://www.minichart.com.sg/2026/05/15/instil-bio-inc-reports-first-quarter-2026-financial-results-8-k-filing-details-and-key-highlights/", "source_name": "Minichart", "published_at": "2026-05-15T14:40:54", "published_display": "15 May 2026 14:40", "sentiment": "positive", "sentiment_pct": 71, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Instil Bio (Nasdaq: TIL) trims Q1 2026 loss and extends cash runway beyond 2027", "summary": "Instil Bio (Nasdaq: TIL) reported significantly reduced losses in Q1 2026, with a GAAP net loss of $4.2 million compared to $28.2 million the previous year. The company announced a strong cash position of approximately $74.7 million, enough to fund operations beyond 2027. Instil ", "url": "https://www.stocktitan.net/sec-filings/TIL/8-k-instil-bio-inc-reports-material-event-3628aa2a5278.html", "source_name": "Stock Titan", "published_at": "2026-05-15T12:40:54", "published_display": "15 May 2026 12:40", "sentiment": "positive", "sentiment_pct": 72, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Instil Bio, Inc. 1Q 2026: Net loss $4.2M, EPS $(0.62) \u2014 10-Q Summary", "summary": "Instil Bio, Inc. reported a significantly narrower net loss in Q1 2026, reaching $4.2 million compared to $28.2 million in Q1 2025, with basic and diluted net loss per share at $(0.62). The company has shifted its pipeline strategy, discontinuing AXN-2510 development to focus on ", "url": "https://www.tradingview.com/news/tradingview:fa55da5e58a94:0-instil-bio-inc-1q-2026-net-loss-4-2m-eps-0-62-10-q-summary/", "source_name": "TradingView", "published_at": "2026-05-15T12:40:54", "published_display": "15 May 2026 12:40", "sentiment": "positive", "sentiment_pct": 61, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Instil Bio Releases Q1 2026 Financial Results", "summary": "Instil Bio, Inc. reported a non-GAAP loss per share of $0.32 and a net loss of $2.2 million for the first quarter of 2026. Despite the loss, common for developing biopharmaceutical firms, Wall Street analysts maintain a positive outlook with consensus ratings reflecting confidenc", "url": "https://news.alphastreet.com/instil-bio-releases-q1-2026-financial-results/", "source_name": "AlphaStreet", "published_at": "2026-05-15T12:40:54", "published_display": "15 May 2026 12:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Instil Bio Reports First Quarter 2026 Financial Results and Provides Corporate Update", "summary": "Instil Bio announced its first quarter 2026 financial results, highlighting a cash position of approximately $74.7 million as of March 31, 2026, which is expected to fund operations beyond 2027. The company is actively evaluating potential acquisitions and in-licensing opportunit", "url": "https://finance.yahoo.com/sectors/healthcare/articles/instil-bio-reports-first-quarter-110000684.html", "source_name": "Market source", "published_at": "2026-05-15T11:09:58", "published_display": "15 May 2026 11:09", "sentiment": "positive", "sentiment_pct": 63, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Instil Bio (NASDAQ: TIL) cuts Q1 loss as 2024 loan and going concern risk loom", "summary": "Instil Bio (NASDAQ: TIL) significantly reduced its net loss to $4.2 million in Q1 2026 from $28.2 million a year prior, primarily due to lower operating expenses from restructuring and discontinuing its AXN-2510 program. Despite this, the company faces a going concern risk as its", "url": "https://www.stocktitan.net/sec-filings/TIL/10-q-instil-bio-inc-quarterly-earnings-report-4dde69351073.html", "source_name": "Stock Titan", "published_at": "2026-05-15T10:40:54", "published_display": "15 May 2026 10:40", "sentiment": "negative", "sentiment_pct": 40, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Instil Bio\u2019s Subsidiary Discontinues Clinical Development of AXN-2510 and Terminates License and Collaboration Agreement with ImmuneOnco", "summary": "", "url": "https://news.google.com/rss/articles/CBMikwFBVV95cUxNWkdLWXdaT0p1SHd1amZ5Y2V4M2VYbng0WFhVemRYcTdBRHpPVFVBYmVxN1JGZDFmTW8xbjd1WlQ0enFzMnF5NnN5LXRGU2ZFV1E0Vl9US1VuMXZFb1B2cWNfUlEzRnZYZEpGc1JvV0ctSzNtanA1UFVFUllTV0xUcDNyNnRYRXZQeEwwb0NiNjlYd28?oc=5", "source_name": "Market source", "published_at": "2026-01-06T08:00:00+00:00", "published_display": "06 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Instil Bio stock falls after subsidiary discontinues AXN-2510 development", "summary": "", "url": "https://news.google.com/rss/articles/CBMizwFBVV95cUxPY1psNnpYWEc5bWlYSWthYmhEeUVCWU1RYTJHNno3RGFYQmJQTEp2d1A5aVhqVmswMDNNU1lZWXdXNHM1X24yb25aTTFYVElsM2VHX3RQdHBHQk41enFaT1hJYXFSczZ5alNnNnozYkZ2ckpPYXROWVN5aHYtQXMwQWlBckZEcFhaMXh5UWdjSlpDQlkzZHhjZnY3Q2RwaW5LN2FnQUFMeGdOdVMwVWo5djMweWdsZkJiS1J2Qk1ndDRUQVFOd3B3WGR0bDZvTzg?oc=5", "source_name": "Investing.com", "published_at": "2026-01-06T08:00:00+00:00", "published_display": "06 Jan 2026 08:00", "sentiment": "negative", "sentiment_pct": 22, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Dallas cancer cell therapy firm Instil Bio goes public with a 32% trading rally", "summary": "", "url": "https://news.google.com/rss/articles/CBMi2gFBVV95cUxPYVRRQ05vRjhORjMxTHNyMzZSblZmNEQ2UDZyQmRpLW9tS0NkUHIzclRYbkFhYnJhTGpXTmdKd1Z0a0g2Nko4TUtNT1VPY1h6ZFRIWmRXNGxQZXZMR0ZuSjktSTIyWi1uSUlEUzlyQWtpNjAwR18xVGJKUjBfZkM1bWNjLTBmQXlXNTZoU3ltWl96SG9CMGdkVU1oOVUxdWtSeGhQaGoza3JOQjlZVW5GT1pnVFIzVGJNMFBxLU1zQ3o5VVlKTzJEcTNJTWotVDI5dGhyLTBFWldTQQ?oc=5", "source_name": "Dallas News", "published_at": "2021-03-19T07:00:00+00:00", "published_display": "19 Mar 2021 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Instil Bio (TIL) Stock Price, News & Analysis $TIL", "summary": "", "url": "https://news.google.com/rss/articles/CBMiWEFVX3lxTE1LLVBDRGw0NXBMZDFncDNqZW5jUFF6elB0WlBzN25vNWVILVVRdGRwRXEtTVk1cnY5SnlITUhUWjZSQjl6RzA4bDI0LTBWSEM0dmloZEh1M3c?oc=5", "source_name": "MarketBeat", "published_at": "2017-08-04T16:07:15+00:00", "published_display": "04 Aug 2017 16:07", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "Avoiding Lag: Real-Time Signals in (TIL) Movement", "summary": "This article analyzes Instil Bio Inc. (NYSE: TIL) using AI models to provide real-time trading signals and strategies. It identifies stable neutral readings in shorter horizons potentially easing long-term weak bias and notes compelling upside potential with no resistance levels ", "url": "https://news.stocktradersdaily.com/news_release/132/Avoiding_Lag:_Real-Time_Signals_in_TIL_Movement_071126044402_1783802642.html", "source_name": "Stock Traders Daily", "published_at": "2026-07-11T16:44:00", "published_display": "11 Jul 2026 16:44", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bronstein, Gewirtz & Grossman, LLC Encourages Instil Bio, Inc. (TIL) Investors to Inquire about Securities Investigation", "summary": "Bronstein, Gewirtz & Grossman, LLC is investigating potential securities claims against Instil Bio, Inc. (NASDAQ:TIL) after its subsidiary, Axion Bio, Inc., announced the discontinuation of clinical development for AXN-2510 and termination of a licensing agreement with ImmuneOnco", "url": "https://natlawreview.com/press-releases/bronstein-gewirtz-grossman-llc-encourages-instil-bio-inc-til-investors", "source_name": "The National Law Review", "published_at": "2026-07-03T12:11:39", "published_display": "03 Jul 2026 12:11", "sentiment": "negative", "sentiment_pct": 19, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of Instil Bio, Inc. \u2013 NASDAQ:TIL", "summary": "This article focuses solely on the \"Price to book forward\" metric for Instil Bio, Inc. (NASDAQ: TIL). The content indicates no specific value, change, or percentage change for this financial metric, stating \"No trades\" and \"Market closed\" in the overview section. The page appears", "url": "https://www.tradingview.com/symbols/NASDAQ-TIL/financials-statistics-and-ratios/price-book-fwd/", "source_name": "TradingView", "published_at": "2026-07-03T09:40:36", "published_display": "03 Jul 2026 09:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBIT forward of Instil Bio, Inc. \u2013 NASDAQ:TIL", "summary": "This page provides financial information for Instil Bio, Inc. (NASDAQ: TIL) on TradingView, specifically focusing on its enterprise value to EBIT forward. The content is primarily a data placeholder within the financial section for the company on the platform.", "url": "https://www.tradingview.com/symbols/NASDAQ-TIL/financials-statistics-and-ratios/enterprise-value-ebit-fwd/", "source_name": "TradingView", "published_at": "2026-06-30T04:40:10", "published_display": "30 Jun 2026 04:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Instil Bio, Inc. \u2013 NASDAQ:TIL", "summary": "This article provides the \"Price to sales forward\" value for Instil Bio, Inc. (NASDAQ: TIL) as listed on TradingView. It appears to be a financial data point without further analysis or context within the presented content. The article indicates the market was closed and no trade", "url": "https://www.tradingview.com/symbols/NASDAQ-TIL/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-29T12:11:30", "published_display": "29 Jun 2026 12:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Instil Bio, Inc. Actuals & Estimates (NASDAQ:TIL)", "summary": "This article provides an overview of Instil Bio, Inc. (NASDAQ:TIL) stock, including its current price, historical performance, analyst forecasts, and financial data. It highlights the stock's recent decline, market capitalization, and upcoming earnings report, while reiterating t", "url": "https://www.tradingview.com/symbols/NASDAQ-TIL/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T16:40:37", "published_display": "26 Jun 2026 16:40", "sentiment": "negative", "sentiment_pct": 18, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "5GT0 Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "This article provides a forecast for Instil Bio, Inc. (5GT0) stock, including a 1-year price target of 6.02 EUR based on one analyst's opinion. It also covers financial details such as past earnings, net income, upcoming earnings dates, and historical stock prices. The Q&A sectio", "url": "https://www.tradingview.com/symbols/TRADEGATE-5GT0/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-26T07:11:14", "published_display": "26 Jun 2026 07:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "TIL Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "This article provides a forecast and price target for Instil Bio, Inc. (TIL) stock, noting analysts' opinions for its future price. It also covers the stock's current performance, historical highs and lows, volatility, market capitalization, and upcoming earnings report. The comp", "url": "https://www.tradingview.com/symbols/NASDAQ-TIL/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-25T17:11:14", "published_display": "25 Jun 2026 17:11", "sentiment": "negative", "sentiment_pct": 38, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Instil Bio Inc (TIL) Technical Analysis: Support, Resistance, Indicators & Moving Averages", "summary": "This article provides a technical analysis of Instil Bio Inc (TIL), outlining its current price momentum, support and resistance levels, and indicator and moving average signals. The stock's current price momentum score is 5.85, and it is trading between a resistance of $8.04 and", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-til/technical", "source_name": "TradingKey", "published_at": "2026-06-24T16:11:14", "published_display": "24 Jun 2026 16:11", "sentiment": "negative", "sentiment_pct": 18, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Instil Bio (Nasdaq:TIL) - Stock Analysis", "summary": "This report provides a comprehensive stock analysis of Instil Bio (Nasdaq: TIL), a biopharmaceutical company with a market cap of US$51.3 million. It details the company's valuation, future growth prospects, past performance, financial health, and dividend policy, noting its curr", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-til/instil-bio", "source_name": "Simply Wall Street", "published_at": "2026-06-23T03:40:37", "published_display": "23 Jun 2026 03:40", "sentiment": "negative", "sentiment_pct": 30, "event_type": "capital_return", "event_label": "Capital return", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Behavioral Patterns of TIL and Institutional Flows", "summary": "This article from Stock Traders Daily discusses the behavioral patterns of Instil Bio Inc. (NYSE: TIL) and institutional flows. It highlights weak sentiment across all horizons supporting a short bias, identifies no clear price positioning signal, and notes no resistance levels a", "url": "https://news.stocktradersdaily.com/news_release/141/Behavioral_Patterns_of_TIL_and_Institutional_Flows_061926022402_1781893442.html", "source_name": "Stock Traders Daily", "published_at": "2026-06-19T14:24:00", "published_display": "19 Jun 2026 14:24", "sentiment": "negative", "sentiment_pct": 39, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Instil Bio Inc (TIL) Valuation: PE, PB & Fair Value Analysis", "summary": "Instil Bio Inc (TIL) currently has a valuation score of 8.27, placing it 154th out of 389 companies in the Biotechnology & Medical Research industry. Its P/E ratio is -1.07, significantly below its recent high but above its recent low. The company has not yet disclosed relevant d", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-til/company-valuation", "source_name": "TradingKey", "published_at": "2026-06-18T13:41:14", "published_display": "18 Jun 2026 13:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Instil Bio Inc (TIL) Institutional Confidence", "summary": "Instil Bio Inc (TIL) has an institutional shareholding score of 5.00, ranking 133rd in the Biotechnology & Medical Research industry. The institutional shareholding proportion is 67.86%, showing a quarter-over-quarter decrease of 0.00%. James Simons is the largest institutional s", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-til/sentiment", "source_name": "TradingKey", "published_at": "2026-06-17T21:09:29", "published_display": "17 Jun 2026 21:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Instil Bio Inc (TIL) Financial Health: Profitability & Balance Sheet Analysis", "summary": "Instil Bio Inc (TIL) has a current financial score of 6.26, ranking 269 out of 388 in the Biotechnology & Medical Research industry, indicating stable financial health but low operating efficiency. The analysis highlights that several key financial data points for categories like", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-til/financial-health", "source_name": "TradingKey", "published_at": "2026-06-17T21:09:29", "published_display": "17 Jun 2026 21:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Instil Bio Inc (TIL) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution", "summary": "The article discusses Instil Bio Inc (TIL)'s revenue breakdown, specifically focusing on its business segments, regional revenue, and profit contribution. It states that relevant financial data for these categories has not yet been disclosed by the company. TradingKey provides th", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-til/revenue", "source_name": "TradingKey", "published_at": "2026-06-17T08:40:07", "published_display": "17 Jun 2026 08:40", "sentiment": "positive", "sentiment_pct": 72, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Instil Bio Inc (TIL) Dividends & Stock Splits: Historical Payouts and Event Timeline", "summary": "This article provides an overview of Instil Bio Inc (TIL)'s dividend history and stock split events. It indicates that the company has not distributed any dividends over the past five years. The article also lists several stock split events, all described as \"Merger 20\u21921\" that oc", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-til/dividend-splits", "source_name": "TradingKey", "published_at": "2026-06-17T08:40:07", "published_display": "17 Jun 2026 08:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Instil Bio Inc (TIL) Earnings Forecast: Future EPS & Revenue Growth Estimates", "summary": "Instil Bio Inc (TIL) has an earnings forecast score of 8.00, placing it 163rd in its industry. Analysts have set an average price target of $88.00 for TIL, with a range from $27.00 to $180.00. Based on ratings from 3 analysts, the general consensus for Instil Bio Inc's stock is a", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-til/earnings", "source_name": "TradingKey", "published_at": "2026-06-17T01:10:15", "published_display": "17 Jun 2026 01:10", "sentiment": "positive", "sentiment_pct": 63, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Instil Bio (NASDAQ: TIL) director receives grant of 6,500 stock options", "summary": "Instil Bio director George Matcham has been granted 6,500 stock options with an exercise price of $7.93 per share. These options will vest in 12 equal monthly installments beginning July 11, 2026, contingent on his continuous service. Unvested portions will fully vest at the next", "url": "https://www.stocktitan.net/sec-filings/TIL/form-4-instil-bio-inc-insider-trading-activity-18671281c2d0.html", "source_name": "Stock Titan", "published_at": "2026-06-12T18:39:32", "published_display": "12 Jun 2026 18:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Instil Bio (TIL) director Gwendolyn Binder awarded 6,500 stock options at $7.93", "summary": "Instil Bio, Inc. Director Gwendolyn Binder has been awarded 6,500 stock options with an exercise price of $7.93 per share. These options are compensation, not a direct purchase, and will vest in 12 monthly installments starting July 11, 2026, contingent on her continuous service.", "url": "https://www.stocktitan.net/sec-filings/TIL/form-4-instil-bio-inc-insider-trading-activity-bd725b906e02.html", "source_name": "Stock Titan", "published_at": "2026-06-12T18:39:32", "published_display": "12 Jun 2026 18:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Instil Bio (TIL) director awarded 6,500 stock options at $7.93 strike", "summary": "Instil Bio director Neil W. Gibson has been granted 6,500 stock options with an exercise price of $7.93 per share, expiring on June 10, 2036. The options will vest in 12 monthly installments starting July 11, 2026, subject to Gibson's continuous service. This grant is a compensat", "url": "https://www.stocktitan.net/sec-filings/TIL/form-4-instil-bio-inc-insider-trading-activity-131178f28e56.html", "source_name": "Stock Titan", "published_at": "2026-06-12T18:39:32", "published_display": "12 Jun 2026 18:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Instil Bio (TIL) director awarded stock options for 6,500 shares at $7.93", "summary": "Instil Bio director R. Kent McGaughy Jr. received a stock option grant for 6,500 shares at an exercise price of $7.93 per share. These options will vest in 12 equal monthly installments starting July 11, 2026, contingent on his continuous service, with full vesting upon certain e", "url": "https://www.stocktitan.net/sec-filings/TIL/form-4-instil-bio-inc-insider-trading-activity-037edc7bdbfd.html", "source_name": "Stock Titan", "published_at": "2026-06-12T04:10:16", "published_display": "12 Jun 2026 04:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[8-K] Instil Bio, Inc. Reports Material Event", "summary": "Instil Bio, Inc. announced the results of its 2026 Annual Meeting of Stockholders. Shareholders elected George Matcham and Neil Gibson as Class II directors and ratified RSM US LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026. ", "url": "https://www.stocktitan.net/sec-filings/TIL/8-k-instil-bio-inc-reports-material-event-c84e8705d1bf.html", "source_name": "Stock Titan", "published_at": "2026-06-11T20:10:32", "published_display": "11 Jun 2026 20:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "(TIL) Movement Within Algorithmic Entry Frameworks", "summary": "This article analyzes Instil Bio Inc. (NYSE: TIL) through algorithmic entry frameworks, noting stable neutral readings in shorter horizons and potential easing of a long-term weak bias. No clear price positioning signal is identified, but the absence of resistance levels above th", "url": "https://news.stocktradersdaily.com/news_release/150/TIL_Movement_Within_Algorithmic_Entry_Frameworks_060826011602_1780938962.html", "source_name": "Stock Traders Daily", "published_at": "2026-06-08T13:16:00", "published_display": "08 Jun 2026 13:16", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "TIL - Instil Bio Inc Stock Price and Quote", "summary": "This article provides a detailed overview of Instil Bio Inc (TIL) stock, including its current price, financial metrics, performance indicators, analyst ratings, and recent news. It highlights the company's financial state, insider transactions, and clinical development updates r", "url": "https://finviz.com/stock?t=TIL", "source_name": "Finviz", "published_at": "2026-05-30T18:40:10", "published_display": "30 May 2026 18:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Instil Bio, Inc. Reports First Quarter 2026 Financial Results \u2013 8-K Filing Details and Key Highlights", "summary": "Instil Bio, Inc. (Nasdaq: TIL) released its Q1 2026 financial results, highlighting a strong cash position of $74.7 million expected to fund operations beyond 2027. The company is actively evaluating potential acquisitions and in-licensing opportunities, while significantly reduc", "url": "https://www.minichart.com.sg/2026/05/15/instil-bio-inc-reports-first-quarter-2026-financial-results-8-k-filing-details-and-key-highlights/", "source_name": "Minichart", "published_at": "2026-05-15T14:40:54", "published_display": "15 May 2026 14:40", "sentiment": "positive", "sentiment_pct": 71, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Instil Bio (Nasdaq: TIL) trims Q1 2026 loss and extends cash runway beyond 2027", "summary": "Instil Bio (Nasdaq: TIL) reported significantly reduced losses in Q1 2026, with a GAAP net loss of $4.2 million compared to $28.2 million the previous year. The company announced a strong cash position of approximately $74.7 million, enough to fund operations beyond 2027. Instil ", "url": "https://www.stocktitan.net/sec-filings/TIL/8-k-instil-bio-inc-reports-material-event-3628aa2a5278.html", "source_name": "Stock Titan", "published_at": "2026-05-15T12:40:54", "published_display": "15 May 2026 12:40", "sentiment": "positive", "sentiment_pct": 72, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Instil Bio, Inc. 1Q 2026: Net loss $4.2M, EPS $(0.62) \u2014 10-Q Summary", "summary": "Instil Bio, Inc. reported a significantly narrower net loss in Q1 2026, reaching $4.2 million compared to $28.2 million in Q1 2025, with basic and diluted net loss per share at $(0.62). The company has shifted its pipeline strategy, discontinuing AXN-2510 development to focus on ", "url": "https://www.tradingview.com/news/tradingview:fa55da5e58a94:0-instil-bio-inc-1q-2026-net-loss-4-2m-eps-0-62-10-q-summary/", "source_name": "TradingView", "published_at": "2026-05-15T12:40:54", "published_display": "15 May 2026 12:40", "sentiment": "positive", "sentiment_pct": 61, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Instil Bio Releases Q1 2026 Financial Results", "summary": "Instil Bio, Inc. reported a non-GAAP loss per share of $0.32 and a net loss of $2.2 million for the first quarter of 2026. Despite the loss, common for developing biopharmaceutical firms, Wall Street analysts maintain a positive outlook with consensus ratings reflecting confidenc", "url": "https://news.alphastreet.com/instil-bio-releases-q1-2026-financial-results/", "source_name": "AlphaStreet", "published_at": "2026-05-15T12:40:54", "published_display": "15 May 2026 12:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Instil Bio Reports First Quarter 2026 Financial Results and Provides Corporate Update", "summary": "Instil Bio announced its first quarter 2026 financial results, highlighting a cash position of approximately $74.7 million as of March 31, 2026, which is expected to fund operations beyond 2027. The company is actively evaluating potential acquisitions and in-licensing opportunit", "url": "https://finance.yahoo.com/sectors/healthcare/articles/instil-bio-reports-first-quarter-110000684.html", "source_name": "Market source", "published_at": "2026-05-15T11:09:58", "published_display": "15 May 2026 11:09", "sentiment": "positive", "sentiment_pct": 63, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Instil Bio (NASDAQ: TIL) cuts Q1 loss as 2024 loan and going concern risk loom", "summary": "Instil Bio (NASDAQ: TIL) significantly reduced its net loss to $4.2 million in Q1 2026 from $28.2 million a year prior, primarily due to lower operating expenses from restructuring and discontinuing its AXN-2510 program. Despite this, the company faces a going concern risk as its", "url": "https://www.stocktitan.net/sec-filings/TIL/10-q-instil-bio-inc-quarterly-earnings-report-4dde69351073.html", "source_name": "Stock Titan", "published_at": "2026-05-15T10:40:54", "published_display": "15 May 2026 10:40", "sentiment": "negative", "sentiment_pct": 40, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Instil Bio\u2019s Subsidiary Discontinues Clinical Development of AXN-2510 and Terminates License and Collaboration Agreement with ImmuneOnco", "summary": "", "url": "https://news.google.com/rss/articles/CBMikwFBVV95cUxNWkdLWXdaT0p1SHd1amZ5Y2V4M2VYbng0WFhVemRYcTdBRHpPVFVBYmVxN1JGZDFmTW8xbjd1WlQ0enFzMnF5NnN5LXRGU2ZFV1E0Vl9US1VuMXZFb1B2cWNfUlEzRnZYZEpGc1JvV0ctSzNtanA1UFVFUllTV0xUcDNyNnRYRXZQeEwwb0NiNjlYd28?oc=5", "source_name": "Market source", "published_at": "2026-01-06T08:00:00+00:00", "published_display": "06 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Instil Bio stock falls after subsidiary discontinues AXN-2510 development", "summary": "", "url": "https://news.google.com/rss/articles/CBMizwFBVV95cUxPY1psNnpYWEc5bWlYSWthYmhEeUVCWU1RYTJHNno3RGFYQmJQTEp2d1A5aVhqVmswMDNNU1lZWXdXNHM1X24yb25aTTFYVElsM2VHX3RQdHBHQk41enFaT1hJYXFSczZ5alNnNnozYkZ2ckpPYXROWVN5aHYtQXMwQWlBckZEcFhaMXh5UWdjSlpDQlkzZHhjZnY3Q2RwaW5LN2FnQUFMeGdOdVMwVWo5djMweWdsZkJiS1J2Qk1ndDRUQVFOd3B3WGR0bDZvTzg?oc=5", "source_name": "Investing.com", "published_at": "2026-01-06T08:00:00+00:00", "published_display": "06 Jan 2026 08:00", "sentiment": "negative", "sentiment_pct": 22, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Dallas cancer cell therapy firm Instil Bio goes public with a 32% trading rally", "summary": "", "url": "https://news.google.com/rss/articles/CBMi2gFBVV95cUxPYVRRQ05vRjhORjMxTHNyMzZSblZmNEQ2UDZyQmRpLW9tS0NkUHIzclRYbkFhYnJhTGpXTmdKd1Z0a0g2Nko4TUtNT1VPY1h6ZFRIWmRXNGxQZXZMR0ZuSjktSTIyWi1uSUlEUzlyQWtpNjAwR18xVGJKUjBfZkM1bWNjLTBmQXlXNTZoU3ltWl96SG9CMGdkVU1oOVUxdWtSeGhQaGoza3JOQjlZVW5GT1pnVFIzVGJNMFBxLU1zQ3o5VVlKTzJEcTNJTWotVDI5dGhyLTBFWldTQQ?oc=5", "source_name": "Dallas News", "published_at": "2021-03-19T07:00:00+00:00", "published_display": "19 Mar 2021 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Instil Bio (TIL) Stock Price, News & Analysis $TIL", "summary": "", "url": "https://news.google.com/rss/articles/CBMiWEFVX3lxTE1LLVBDRGw0NXBMZDFncDNqZW5jUFF6elB0WlBzN25vNWVILVVRdGRwRXEtTVk1cnY5SnlITUhUWjZSQjl6RzA4bDI0LTBWSEM0dmloZEh1M3c?oc=5", "source_name": "MarketBeat", "published_at": "2017-08-04T16:07:15+00:00", "published_display": "04 Aug 2017 16:07", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [{"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNYmZ3aHMyMjBuNmlEUGN6NWZBZV85cEFWNndJaVNoNEVYNk84MlNKRXJ0RXpRQl9wN1RsekhxM3loY1RRNDJhTnVremtReHhLQWVHS053VzRBUTduSkdqRGt1YkxMMThqZHoydElPX1Zfd3hEMi15VlRwRGRvZ2JqRDFneVVxN0JCYzQ4QlV5TTBEOWx3?oc=5", "source_name": "Market source", "published_at": "2026-07-16T18:49:22+00:00", "published_display": "16 Jul 2026 18:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "sector": []}, "total_fetched": 95, "total_relevant": 43, "sentiment_summary": {"positive": 7, "negative": 9, "neutral": 27, "score": 48, "total": 43, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 75, "events": [{"event": "general", "label": "Market update", "weight": 9.9, "count": 18}, {"event": "earnings", "label": "Earnings", "weight": 8.11, "count": 17}, {"event": "deals", "label": "Deals and strategy", "weight": 1.65, "count": 3}, {"event": "liquidity", "label": "Balance sheet", "weight": 1.1, "count": 2}, {"event": "regulatory", "label": "Regulatory and legal", "weight": 0.55, "count": 1}, {"event": "capital_return", "label": "Capital return", "weight": 0.55, "count": 1}], "positive_events": 7, "negative_events": 9}, "market_context": {"has_market_context": true, "latest_close": 7.7, "latest_week": "2026-07-10", "one_week_move": -0.4, "four_week_move": -2.8, "twelve_week_move": -13.3, "trend_signal": "0", "trend_label": "Trend inactive", "trend_tone": "negative", "market_dynamics": 0.577824, "market_dynamics_buy_signal": false, "relative_strength": -52.506144, "fair_value_gap": -51.9, "fair_value_label": "Below fair value", "fair_value_tone": "positive", "expectation_direction": "negative", "expectation_probability": 44.5305, "reaction_label": "Price digesting", "reaction_tone": "neutral", "market_sentence": "-0.4% over one week, -2.8% over four weeks, trend inactive, and below fair value."}, "interpretation": {"label": "Balanced read", "tone": "neutral", "classification": "balanced", "summary": "News tone and price action are not far from neutral.", "confidence": 49, "badges": ["Value support"], "opportunities": ["Price is below fair value while news tone is not negative."], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "Market source", "count": 8}, {"label": "TradingView", "count": 8}, {"label": "TradingKey", "count": 7}, {"label": "Stock Titan", "count": 7}, {"label": "Stock Traders Daily", "count": 3}, {"label": "simplywall.st", "count": 2}, {"label": "The National Law Review", "count": 1}, {"label": "Simply Wall Street", "count": 1}], "tiers": [{"label": "Direct company coverage", "count": 34}, {"label": "Industry context", "count": 9}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 18}, {"label": "Earnings", "count": 17}, {"label": "Deals and strategy", "count": 3}, {"label": "Balance sheet", "count": 2}, {"label": "Regulatory and legal", "count": 1}, {"label": "Capital return", "count": 1}, {"label": "Analyst action", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "48/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Balanced read", "tone": "neutral", "text": "News tone and price action are not far from neutral."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "75/100 classification confidence."}, {"label": "Company focus", "value": "34", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "0", "tone": "neutral", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend inactive", "tone": "negative", "text": "-0.4% over one week, -2.8% over four weeks, trend inactive, and below fair value."}, {"label": "Latest direct headline", "value": "Neutral", "tone": "neutral", "text": "Avoiding Lag: Real-Time Signals in (TIL) Movement"}], "updated_at": "2026-07-17T16:57:32.831167+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}